The U.S. Food and Drug Administration has approved the expanded use of LINZESS (linaclotide) for pediatric patients 2 years of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE